Somewhat Favorable News Coverage Somewhat Unlikely to Impact Keryx Biopharmaceuticals (KERX) Stock Price

News stories about Keryx Biopharmaceuticals (NASDAQ:KERX) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Keryx Biopharmaceuticals earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.1040927325507 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

KERX has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 16th. ValuEngine cut shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, November 10th. Finally, Stifel Nicolaus dropped their price objective on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating on the stock in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $7.44.

Shares of Keryx Biopharmaceuticals (NASDAQ KERX) remained flat at $$4.86 during trading hours on Monday. 486,000 shares of the company traded hands, compared to its average volume of 1,041,008. Keryx Biopharmaceuticals has a fifty-two week low of $4.33 and a fifty-two week high of $8.38. The stock has a market cap of $598.50, a PE ratio of -3.24 and a beta of 4.92. The company has a current ratio of 4.46, a quick ratio of 3.76 and a debt-to-equity ratio of 13.95.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The business had revenue of $15.00 million for the quarter, compared to analysts’ expectations of $18.88 million. During the same quarter last year, the business earned ($0.39) EPS. The company’s quarterly revenue was up 138.1% on a year-over-year basis. equities analysts expect that Keryx Biopharmaceuticals will post -1.35 earnings per share for the current year.

In other news, COO Christine A. Carberry sold 9,048 shares of the stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $4.87, for a total transaction of $44,063.76. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 18,910 shares of company stock worth $101,093 in the last quarter. Insiders own 2.58% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Markets Daily and is the property of of Markets Daily. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/01/22/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-keryx-biopharmaceuticals-kerx-stock-price.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Insider Buying and Selling by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply